BRIEF

on Nanohale AG (ETR:FYB)

Formycon AG Sees Mixed Q3/26 Results Amid Competitive Market Pressures

Stock price chart of Nanohale AG (EBR:FYB) showing fluctuations.

First Berlin Equity Research has published an update on Formycon AG, reaffirming a "Buy" recommendation. The target price has been adjusted from €50 to €46. Q3/26 sales rose by 35.2% to €14.2 million, slightly surpassing expectations due to milestone income from the Keytruda biosimilar candidate, FYB206. However, quarterly EBITDA fell short of projections at €-5.5 million, driven by higher expenditures on FYB206.

The commercial landscape is changing for the biosimilars of ranibizumab and ustekinumab, prompting revenue forecast reductions. Formycon recorded impairments of €39 million and €82 million for these products. The reference products for new biosimilar candidates FYB210 and FYB286, which contribute significantly to enterprise valuation, offer new growth avenues. FYB206 remains the primary value driver for Formycon, with milestones expected to exceed related costs by year-end.

R. E.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Nanohale AG news